Clinical Trial: A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of HRS-4139 in Healthy Participants

U.S., Sept. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07802964) titled 'A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of HRS-4139 in Healthy Participants' on Aug. 31.

Brief Summary: This Phase I clinical study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral dose of HRS-4139 in healthy participants.

Study Start Date: Sept., 2026

Study Type: INTERVENTIONAL

Condition: Psoriasis Vulgaris

Intervention: DRUG: HRS-4139 Tablet

HRS-4139 tablet.

DRUG: HRS-4139 Placebo

HRS-4139 placebo.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Published by HT Di...